Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2000

View Archived Issues

University of Utah to evaluate efficacy of glucosamine and chondroitin in treating OA

Pherin discovers human vomeronasal organ receptor gene

Merger of Cambridge NeuroScience and CeNeS completed

Genzyme Biosurgery created

Phase III general surgery trial demonstrates significant benefits for Oxygent

Past 12 months include significant events at Interneuron

Novel nonviral gene delivery system provides improved transfection efficiency in cells

Shearwater to pegylate Regeneron's obesity Rx

Development plans for carbapenem E-1010 revealed by Eisai

SB granted rights to new GERD therapy in all markets outside Korea

NDA for UT-15 will not require FDA advisory committee review

The Medicines Company's Angiomax approved by FDA for use in angioplasty

Oxigene begins phase II trials with declopramide

Phase I trials commence for Idun caspase inhibitor

FDA advisory committee cancels January meeting

Mitsubishi-Tokyo begins overseas development of new drug for Alzheimer's disease

Antiproliferative and antiinvasive effects determined for ZD-1839 in breast cancer

Further evidence supporting the use of SAANDs in breast cancer presented in San Antonio

Lutrin, a photosensitizer with redox activity, shows promise in recurrent breast cancer

Antiestrogenic/estrogenic effects of EM-652.HCl and lasofoxifene compared

Treatment of autoimmune diseases with Rituxan

Antisense compounds from Isis modulate PPARgamma expression

Water-soluble PARP prodrugs emerge from U.K. university research

Bayer designs improved camptothecin derivatives for cancer therapy

Melatonergic agents synthesized at ADIR and their use

More stable salts of thrombin inhibitors prepared at BASF

Novel polymers for conjugation with proteins and peptides designed by Enzon

Improved compositions of LHRH or somatostatin analogues described in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...